T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Multiple Myeloma

In brief

Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. Three days following the transplant, patients will receive an infusion of a large number of expanded immune cells. The goal of the study will be to determine the safety as well as potential efficacy of this treatment.

Key facts

Study ID

NCT00048464

Run by

Xcyte Therapies

People needed

35

Starts

2002-10-01

Last updated by the study team

2006-11-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cedars Sinai Medical Center — Los Angeles, California, United States
• University of California, San Diego — San Diego, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Johns Hopkins Medical Institute — Baltimore, Maryland, United States
• Washington University — St Louis, Missouri, United States
• Hackensack University — Hackensack, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.